Abstract
Background
Pulmonary embolism (PE) is recognized as an important complication in patients undergoing hip fracture surgery. However, clinical evidence demonstrating the effectiveness of pharmacological thromboprophylaxis, including fondaparinux, is limited because the occurrence of postoperative PE after hemiarthroplasty is very low. The goal of this study was to analyze the effect of fondaparinux in reducing PE following hemiarthroplasty for femoral neck fracture using large-scale retrospective data.
Methods
Employing data from the Japanese Diagnosis Procedure Combination database from July 1 to December 31 between 2007 and 2010, we retrospectively identified 22,776 patients who underwent hemiarthroplasty for femoral neck fracture; we included those who received mechanical prophylaxis alone (n = 17,984) and those who received both mechanical prophylaxis and pharmacological prophylaxis with fondaparinux (n = 4,792). Logistic regression analysis was performed to compare the occurrence of postoperative PE with adjustment for sex, age, comorbidities, and type and duration of anesthesia.
Results
The mean age of the patients was 79.5 ± 9.4 years. Overall, postoperative PE occurred in 189 (0.83 %) patients. The rate of postoperative PE in the fondaparinux group (0.61 %) was lower than in the control group (0.89 %), although the difference was not significant in the univariate analysis (odds ratio [OR] 0.68; p = 0.055). In the multivariate analysis, the fondaparinux group showed a significantly lower rate of postoperative PE than the group receiving mechanical prophylaxis alone (OR 0.67; p = 0.047). General anesthesia and a longer duration of anesthesia were significant risk factors for postoperative PE.
Conclusions
Fondaparinux combined with mechanical prophylaxis is more effective in preventing postoperative PE following hemiarthroplasty for femoral neck fracture than mechanical prophylaxis alone.
Similar content being viewed by others
References
Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367(9527):2010–8.
Orimo H, Yaegashi Y, Onoda T, Fukushima Y, Hisoi T, Sakata K. Hip fracture incidence in Japan: estimates of new patients in 2007 and 20-year trends. Arch Osteoporos. 2009;4(1–2):71–7.
Dahl OE, Caprini JA, Colwell CW Jr, Frostick SP, Haas S, Hull RD, Laporte S, Stein PD. Fatal vascular outcomes following major orthopedic surgery. Thromb Haemost. 2005;93(5):860–6.
Ytter YF, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwel CW Jr. Prevention of VTE in orthopaedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e278S–325S.
Powers PJ, Gent M, Jay RM, Julian DH, Turpie AG, Levine M, Hirsh J. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med. 1989;149(4):771–4.
Jørgensen PS, Knudsen JB, Broeng L, Josephsen L, Bjerregaard P, Hagen K, Jørgensen PK, Tørholm C. The thromboprophylactic effect of a low-molecular-weight heparin (Fragmin) in hip fracture surgery. A placebo-controlled study. Clin Orthop Relat Res. 1992;278:95–100.
Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345(18):1298–304.
Nagase Y, Yasunaga H, Hiromasa H, Horiguchi H, Shoda N, Kadono Y, Matsuda S, Nakamura K, Tanaka S. Risk factors for pulmonary embolism and the effects of fondaparinux after total hip and knee arthroplasty: a retrospective observational study with use of a national database in Japan. J Bone Jt Surg Am. 2011;93(24):e146.
Kitamukai O, Sakuma M, Takahashi T, Kagaya Y, Watanabe J, Shirato K. Incidence and characteristics of pulmonary thromboembolism in Japan 2000. Intern Med. 2003;42(11):1090–4.
Schneider D, Lilienfeld DE, Im W. The epidemiology of pulmonary embolism: racial contrasts in incidence and in-hospital case fatality. J Natl Med Assoc. 2006;98(12):1967–72.
Yasunaga H, Hashimoto H, Horiguchi H, Miyata S, Matsuda S. Variation in cancer surgical outcomes associated with physician and nurse staffing: a retrospective observational study using the Japanese Diagnosis Procedure Combination database. BMC Health Serv Res. 2012;28(12):129.
Yasunaga H, Horiguchi H, Kuwabara K, Matsuda S, Fushimi K, Hashimoto H, Ayanian JZ. Outcomes after laparoscopic or open distal gastrectomy for early-stage gastric cancer: a propensity-matched analysis. Ann Surg. 2013;257(4):640–6.
Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I9–16.
Wattanakit K, Cushman M, Stehman BC, Heckbent SR, Folsom AR. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol. 2008;19(1):135–40.
Piazza G, Goldhaber SZ, Kroll A, Goldberg RJ, Emery C, Spencer FA. Venous thromboembolism in patients with diabetes mellitus. Am J Med. 2012;125(7):709–16.
Kawasaki T, Kambayashi J, Sakon M. Hyperlipidemia: a novel etiologic factor in deep vein thrombosis. Thromb Res. 1995;79(2):147–51.
Rosencher N, Vielpeau C, Emmerich J, Fagnani F, Samama CM, ESCORTE group. Venous thromboembolism and mortality after hip fracture surgery: the ESCORTE study. J Thromb Haemost. 2005;3(9):2006–14.
Pulmonary Embolism Prevention (PEP) Trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary embolism prevention (PEP) trial. Lancet. 2000;355(9212):1295–302.
McNamara I, Sharma A, Prerost T, Paker M. Symptomatic venous thromboembolism following a hip fracture. Acta Orthop. 2009;80(6):687–92.
Sasaki S, Miyakoshi N, Matsuura H, Saito H, Nakanishi T, Kudo Y, Fujiya T, Shimada Y. Prospective study on the efficacies of fondaparinux and enoxaparin in preventing venous thromboembolism after hip fracture surgery. J Orthop Sci. 2011;16(1):64–70.
Sasaki S, Miyakoshi N, Matsuura H, Saitoh H, Kudoh D, Shimada Y. Prospective randomized controlled trial on the effect of fondaparinux sodium for the prevention of venous thromboembolism after hip fracture surgery. J Orthop Sci. 2009;14:491–6.
Khatod M, Inacio MC, Bini SA, Paxton EW. Pulmonary embolism prophylaxis in more than 30,000 total knee arthroplasty patients: is there a best choice? J Arthroplasty. 2012;27(2):167–72.
Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol. 2004;24(6):1015–22.
Arcelus JI, Monreal M, Caprini JA, Guisado JG, Soto MJ, Núñez MJ, Alvárez JC, RIETE investigators. Clinical presentation and time-course of postoperative venous thromboembolism: results from the RIETE registry. Thromb Haemost. 2008;99(3):546–51.
Acknowledgments
This study was funded by grants from the Ministry of Health, Labour and Welfare, Japan (Research on Policy Planning and Evaluation grant number H22-Policy-031; Research on Intractable Diseases grant number H23-Nanchi-032); the Ministry of Education, Culture, Sports, Science and Technology, Japan (Scientific Research B, No. 22390131); and the Council for Science and Technology Policy, Japan (Funding Program for World-Leading Innovative R&D on Science and Technology FIRST program grant number 0301002001001).
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Tsuda, Y., Yasunaga, H., Horiguchi, H. et al. Effects of fondaparinux on pulmonary embolism following hemiarthroplasty for femoral neck fracture: a retrospective observational study using the Japanese Diagnosis Procedure Combination database. J Orthop Sci 19, 991–996 (2014). https://doi.org/10.1007/s00776-014-0607-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00776-014-0607-2